Cancer of Head and Neck Clinical Trial
Official title:
Effects of Oral Cancer Treatments on Upper Esophageal Opening During Swallowing
The purpose of this study is to investigate post-operative and post-radiation upper esophageal sphincter opening measures in oral cancer patients, compare measures to age- and gender-matched healthy adults, and determine relationships with patient swallowing outcomes and quality of life.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Oral cancer that includes tongue or floor of mouth clinical stage T1 or higher - May have disease that extends to base of tongue or other site as long as floor of mouth or tongue are involved - Adults at least 18 years of age Exclusion Criteria: - Oral cancer of the lip, cheek, palate or other site not impacting tongue or floor of mouth musculature - History of floor of mouth, tongue base, pharyngeal or laryngeal surgical resection - History of radiation treatment to the head and neck - History of dysphagia prior to onset of oral cancer symptoms - Allergy to lidocaine, barium, adhesive tape or apple flavoring - Woman of childbearing years who are pregnant |
Country | Name | City | State |
---|---|---|---|
United States | University of Wisconsin | Madison | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
University of Wisconsin, Madison |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Upper Esophageal Maximum Admittance as measured by HRM among time points of oral cancer treatment. | This measure provides understanding of how well throat muscles pull the upper esophagus open to allow flow of liquid or food from the throat to the esophagus. | Approximately 4 weeks (post-surgery), and up to 6 months (3 months post-radiation) | |
Primary | Change in Upper Esophageal Integrated Relaxation Pressure (IRP) as measured by HRM | This measure indicates how well the muscles of the upper esophageal sphincter relax to allow liquid and food to pass through. | Approximately 4 weeks (post-surgery), and up to 6 months (3 months post-radiation) | |
Primary | Change in Hypopharyngeal Pressure at Nadir Impedence (PNI) as measured by HRM | This measure indicates how well the upper esophagus stretches open to accept the liquid or food. | Approximately 4 weeks (post-surgery), and up to 6 months (3 months post-radiation) | |
Secondary | Change in the MD Anderson Dysphagia Inventory (MDADI) Scores among time points of oral cancer treatment | Measurement of swallowing-related quality of life. This patient-rated tool has a maximum score of 100 points total across 20 questions, where the highest score indicates better overall swallow-related quality of life. | Approximately 4 weeks (post-surgery), and up to 6 months (3 months post-radiation) | |
Secondary | Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) Grading Scale Score | Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) grade of 0 to 4, where lower grade reflects better swallow function | Approximately 4 weeks (post-surgery), and up to 6 months (3 months post-radiation) | |
Secondary | Statistical Correlation between MDADI and Maximum Admittance | Approximately 4 weeks (post-surgery), and up to 6 months (3 months post-radiation) | ||
Secondary | Statistical Correlation between DIGEST and Maximun Admittance | Approximately 4 weeks (post-surgery), and up to 6 months (3 months post-radiation) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT05331131 -
Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity Associated With Head and Neck Chemoradiotherapy: A Phase 2, Simon 2-stage Trial
|
Phase 2 | |
Completed |
NCT05269342 -
Nurse-led Exercise Improves Shoulder Pain, Shoulder Disability, and Quality of Life in Head and Neck Cancer
|
N/A | |
Completed |
NCT03574870 -
Wearable Sensor for Biometrics During Locoregional Therapy for Head and Neck Cancer
|
N/A | |
Recruiting |
NCT04804852 -
Assessment of the Prevalence of Sarcopenia by CT Scan in Patients Diagnosed With Head & Neck Cancer
|
||
Active, not recruiting |
NCT04617678 -
A Comprehensive Approach to Head and Neck Cancer Prehabilitation
|
N/A | |
Completed |
NCT03419741 -
Brain Stimulation For Cancer Smokers
|
N/A | |
Recruiting |
NCT02528955 -
De-Intensification Radiotherapy Postoperative Head Neck
|
Phase 2 | |
Completed |
NCT00318890 -
Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck
|
Phase 1/Phase 2 | |
Recruiting |
NCT05179824 -
Tempus Priority Study: A Pan-tumor Observational Study
|
||
Recruiting |
NCT05316974 -
Lymphoedema Among Persons With Head- and Neck Cancer
|
||
Not yet recruiting |
NCT03954691 -
Targeting Potassium Channels to Reprogram Glioblastoma Microenvironment: in Vitro and in Vivo Studies
|
||
Active, not recruiting |
NCT03760471 -
Palliative and Oncology Care Intervention: Symptom COACH
|
N/A | |
Completed |
NCT04554667 -
Heavy Lifting Strength Training in Head and Neck Cancer Survivors
|
Phase 1 | |
Completed |
NCT02869399 -
Tertiary Prevention of Head and Neck Cancer With a Dietary Intervention
|
N/A | |
Completed |
NCT02366611 -
Pain Control Using Neuromodulation in Patients Undergoing Definitive Chemoradiotherapy for Head and Neck Cancer
|
N/A | |
Completed |
NCT02075112 -
Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in SCC of the Head and Neck
|
Phase 1 | |
Completed |
NCT00798655 -
Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
|
Phase 2 | |
Completed |
NCT02900911 -
Swallowing Rehabilitation in Patients With Head and Neck Cancer Receiving Radiotherapy
|
N/A | |
Completed |
NCT01317589 -
Treatment of Pain in Head-and-Neck Cancer Patients: is Methadone More Effective?
|
Phase 4 | |
Completed |
NCT03841175 -
Forecasts Impact of the Pre-therapeutic TEP-TDM in the 18-FDG Restaging of Upper Aero-digestive Tract Cancers
|